Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | PRKCA | P17252 | 2/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647622 | 0.92 | MAPK1 (0.48) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL18641755 | 0.92 | MAPK1 (0.48) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL20618585 | 0.92 | MAPK1 (0.48) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL25410411 | 0.91 | MAPK1 (0.58) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24163833 | 0.91 | MAPK1 (0.58) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL25411427 | 0.91 | MAPK1 (0.58) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL22646074 | 0.91 | MAPK1 (0.58) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL23769753 | 0.91 | MAPK1 (0.58) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL23343368 | 0.91 | MAPK1 (0.58) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL24164561 | 0.91 | MAPK1 (0.58) | MAPTMAPK1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | ARES CAPITAL CORPORATION, AS AGENT | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | TTPA, SREBF1, SREBF2 | MAPT 3188/4885MAPK1 4225/4885PRKCA 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.